Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,422,792

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Johnson & Johnson (JNJ) Stock Moves -0.77%: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $159.02, moving -0.77% from the previous trading session.

Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar

Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Johnson & Johnson (JNJ) Stock Moves -0.17%: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $162.20, moving -0.17% from the previous trading session.

The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Johnson & Johnson, Pfizer and Morgan Stanley

Meta Platforms, Walmart, Johnson & Johnson, Pfizer and Morgan Stanley are part of the Zacks top Analyst Blog.

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

Smart Beta ETF report for LVHD

Sheraz Mian headshot

Top Analyst Reports for Meta Platforms, Walmart & Johnson & Johnson

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and Johnson & Johnson (JNJ).

Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?

Style Box ETF report for IWX

Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $163.99, marking a +0.25% move from the previous day.

AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals

AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.

Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar

Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America. The company discontinues the development of GT005 in geographic atrophy.

AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo

Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.

Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?

Style Box ETF report for VYM

J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe

J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Kinjel Shah headshot

Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe

The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.

Kinjel Shah headshot

Pharma Stock Roundup: J&J to End Hypertension Study & Other Regulatory Updates

J&J (JNJ) to end a late-stage study on macitentan for CTEPH. Merck's (MRK) Ebola vaccine gets approval in Europe for use in kids.

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $160.03, moving +1.28% from the previous trading session.

J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit

The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.

Andrew Rocco headshot

Stocks on the Mend: A Mean Reversion Duo

September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $160.48, marking a -0.74% move from the previous day.